THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) — Autonomix Scientific, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a clinical tool corporate devoted to advancing precision nerve-targeted therapies, nowadays introduced that its summary titled, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” has been decided on as a Featured Summary for podium presentation on the Society of Interventional Radiology (SIR) 2026 Annual Medical Assembly, happening April 11–15, 2026, in Toronto, Canada.
The summary is amongst a make a selection staff identified for its clinical benefit and scientific importance and may also be highlighted within the Magazine of Vascular and Interventional Radiology (JVIR) 2026 Annual Medical Assembly Complement.
The presentation might be delivered through Dr. Lindsay Machan on Saturday, April 12, from 4:03 PM to 4:12 PM.
The learn about evaluates long-term results of denervation the usage of transvascular radiofrequency (RF) energy-based ablation in sufferers with pancreatic adenocarcinoma, that specialize in sustained ache mitigation, a space of important unmet want for sufferers affected by this competitive illness.
“Being selected for a Featured Abstract presentation at SIR underscores the importance of advancing novel approaches to address cancer-related pain,” mentioned Brad Hauser, CEO of Autonomix. “We are encouraged by the growing body of evidence supporting our technology and look forward to sharing these important findings with the interventional radiology community.”
Pancreatic adenocarcinoma is frequently related to critical, difficult-to-manage ache that considerably affects high quality of lifestyles. Autonomix Scientific’s proprietary era goals to focus on and modulate nerve job thru a minimally invasive, transvascular means, probably providing a brand new healing possibility for ache control.
The Society of Interventional Radiology Annual Medical Assembly is a premier international tournament bringing in combination physicians, researchers, and trade leaders to proportion state-of-the-art analysis and developments in minimally invasive, image-guided treatments. For more info, please consult with the convention web site.
About Autonomix Scientific, Inc.
Autonomix is a clinical tool corporate considering advancing cutting edge applied sciences to revolutionize how sicknesses involving the apprehensive device are identified and handled. The Corporate’s first-in-class platform device era features a catheter-based microchip sensing array that can be capable of hit upon and differentiate neural indicators with better sensitivity than recently to be had applied sciences. We imagine this may increasingly permit, for the primary time ever, transvascular analysis and remedy of sicknesses involving the peripheral apprehensive device nearly any place within the frame.
We’re to begin with creating this era for the remedy of ache, with preliminary trials considering pancreatic most cancers, a situation that reasons debilitating ache and is with out a dependable resolution. Our era constitutes a platform to handle dozens of possible indications, together with cardiology, high blood pressure and protracted ache control, throughout a large illness spectrum. Our era is investigational and has no longer but been cleared for advertising and marketing in the US.
For more info, consult with autonomix.com and connect to the Corporate on X, LinkedIn, Instagram and Fb.
Ahead Taking a look Statements
One of the most statements on this unencumber are “forward-looking statements,” which contain dangers and uncertainties. Such forward-looking statements can also be recognized by means of phrases akin to “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Ahead-looking statements on this press unencumber come with expectancies in regards to the possible effectiveness and scientific advantages of Autonomix’s nerve-targeted therapies for pancreatic most cancers ache and different stipulations.
Even supposing Autonomix believes that the expectancies mirrored in those forward-looking statements are in accordance with cheap assumptions, there are a selection of dangers and uncertainties that would reason precise effects to vary materially from such forward-looking statements. You’re steered to rigorously assessment and believe any cautionary statements and different disclosures, together with the statements made underneath the heading “Risk Factors” and in different places within the Annual Document on Shape 10-Ok filed with the U.S. Securities and Trade Fee (SEC) on Would possibly 29, 2025, and every so often, our different filings with the SEC. Ahead-looking statements talk simplest as of the date of this press unencumber and Autonomix does no longer adopt any responsibility to replace any forward-looking statements excluding as could also be required through legislation.
